Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 3 & 4

Program Dates: October 24th, 2022 - October 23rd, 2023
Credits: 1.0 AMA PRA Category 1 Credit™

Evidence Based Dietary and Pharmacologic Approaches to Manage Patients with Hyperkalemia and Associated Comorbidities – Modules 3 & 4

Program Overview

This CME program will highlight evidence based dietary and pharmacologic approaches to manage patients with hyperkalemia. In module 3, Dr. George Bakris will analyze the clinical trial data for newer therapeutic options to treat patients with hyperkalemia. Following, Dr. Matthew Weir will lead a faculty discussion to further delve into these trials and how they relate to patient care. Next, in module 4, Dr. Deborah Clegg will review how to best treat patients with hyperkalemia and associated comorbidities from an interprofessional approach, along with a patient case. Drs. Clegg and Bakris will then discuss the challenges of monitoring patients’ nutrition intake through an interactive panel discussion.

Target Audience

Nephrologists, Primary Care Physicians, Internal Medicine, Nutritionists, Renal Dieticians and other healthcare providers who treat patients with hyperkalemia


Module 3 – Clinical Trial Update for Newer Therapeutic Options to Treat Hyperkalemia

Module 4 – A Multi-disciplinary and Interprofessional Approach to Best Treat Hyperkalemia and Associated Comorbidities – Challenging Patient Case Studies

Learning Objectives

  1. Understand current data on newer therapeutic options to treat hyperkalemia
  2. Discuss a multi-disciplinary and interprofessional approach to best treat hyperkalemia and associated comorbidities


George Bakris, MD
Professor of Medicine
Director, AHA Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL



Deborah Clegg, PhD
Professor, Department of Internal Medicine
Foster School of Medicine
Vice President for Research
Texas Tech University Health Sciences Center El Paso
El Paso, TX



Matthew Weir, MD
Professor and Director
Division of Nephrology
University of Maryland School of Medicine
Baltimore, MD



Disclosures of Relevant Financial Relationships

It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
George Bakris, MD Consultant/Advisor: Alnylam; AstraZeneca; Bayer; DiaMedica Therapeutics; InREGEN; Ionis; Janssen; KBP Biosciences; Novo Nordisk; Quantum Genomics
Deborah Clegg, PhD Nothing to disclose
Matthew Weir, MD Consultant/Advisor: Akebia; AstraZeneca; Bayer; Boehringer Ingelheim; GSK; Janssen; Merck; Novo Nordisk; Vifor Pharma

Planners and Peer Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Credit Designation Statements

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Financial Support

This activity has been supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and AstraZeneca do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web